MX2022013620A - Proteina bifuncional frente a pd-1 y tgf-beta. - Google Patents

Proteina bifuncional frente a pd-1 y tgf-beta.

Info

Publication number
MX2022013620A
MX2022013620A MX2022013620A MX2022013620A MX2022013620A MX 2022013620 A MX2022013620 A MX 2022013620A MX 2022013620 A MX2022013620 A MX 2022013620A MX 2022013620 A MX2022013620 A MX 2022013620A MX 2022013620 A MX2022013620 A MX 2022013620A
Authority
MX
Mexico
Prior art keywords
tgf
bifunctional protein
beta
protein against
bifunctional
Prior art date
Application number
MX2022013620A
Other languages
English (en)
Spanish (es)
Inventor
Yingchun Li
Wei Zhao
Xiquan Zhang
Haili Lv
Lianxiang Xie
Zhewen Zhang
Yu Qin
Yanju Cheng
Peng Lv
Tiantian Li
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2022013620A publication Critical patent/MX2022013620A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
MX2022013620A 2020-04-29 2021-04-26 Proteina bifuncional frente a pd-1 y tgf-beta. MX2022013620A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010359751 2020-04-29
PCT/CN2021/089837 WO2021218895A1 (zh) 2020-04-29 2021-04-26 针对PD-1和TGF-β的双功能蛋白

Publications (1)

Publication Number Publication Date
MX2022013620A true MX2022013620A (es) 2023-01-30

Family

ID=78331777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013620A MX2022013620A (es) 2020-04-29 2021-04-26 Proteina bifuncional frente a pd-1 y tgf-beta.

Country Status (9)

Country Link
US (1) US20230235057A1 (https=)
EP (1) EP4144763A4 (https=)
JP (2) JP7711095B2 (https=)
KR (1) KR20230003178A (https=)
AU (1) AU2021263650A1 (https=)
BR (1) BR112022022020A2 (https=)
CA (1) CA3181579A1 (https=)
MX (1) MX2022013620A (https=)
WO (1) WO2021218895A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN116970086A (zh) * 2022-04-29 2023-10-31 广东菲鹏制药股份有限公司 一种重组抗体及其应用
WO2025251034A1 (en) * 2024-05-31 2025-12-04 Amgen Inc. Purification method

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD120103A1 (https=) 1975-07-07 1976-05-20
BR112016014952A2 (pt) * 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
EP3770171A1 (en) * 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
MY202480A (en) * 2017-05-12 2024-04-30 Shanghai hengrui pharmaceutical co ltd Fusion protein containing tgf- receptor and medicinal uses thereof
US20200140547A1 (en) * 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
CN112585165B8 (zh) * 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
MX2020011684A (es) * 2018-05-04 2020-12-10 Merck Patent Gmbh Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
US10597453B2 (en) * 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
AU2019301070B2 (en) * 2018-07-09 2025-09-11 Precigen, Inc. Fusion constructs and methods of using thereof
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN114340735B (zh) * 2019-06-28 2024-11-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
CN110734498A (zh) * 2019-10-15 2020-01-31 上海科棋药业科技有限公司 一种用于解除免疫抑制的融合蛋白及其应用
CN114616251B (zh) * 2019-10-21 2024-05-24 南京维立志博生物科技有限公司 靶向PD-1和TGFβ的重组蛋白

Also Published As

Publication number Publication date
WO2021218895A1 (zh) 2021-11-04
US20230235057A1 (en) 2023-07-27
AU2021263650A1 (en) 2023-01-19
JP7711095B2 (ja) 2025-07-22
JP2025148434A (ja) 2025-10-07
JP2023523083A (ja) 2023-06-01
EP4144763A1 (en) 2023-03-08
KR20230003178A (ko) 2023-01-05
BR112022022020A2 (pt) 2023-01-31
EP4144763A4 (en) 2024-05-29
CA3181579A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
MX2022013620A (es) Proteina bifuncional frente a pd-1 y tgf-beta.
ZA202210065B (en) Interleukin-21 muteins and methods of treatment
CL2020002305A1 (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1
WO2021163064A3 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
DOP2023000165A (es) Anticuerpos de unión a cd3
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
CO2018003973A2 (es) Proteínas de unión a pd-1 y métodos para usarlas
CL2024003715A1 (es) Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso.
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
EP4566621A3 (en) Dll3/cd3 binding proteins for the treatment of cancer
MX2019014318A (es) Proteinas de union a nectina-4 y metodos de uso de las mismas.
WO2017172260A8 (en) Binding proteins and methods of use thereof
MX2021014966A (es) Anticuerpos anti-cd3 dependientes de ph modificados geneticamente y metodos para su generacion y uso.
EP4606383A3 (en) Anti-cd3 antibody and molecules comprising the antibody
MX2022003039A (es) Metodo de seleccion de donantes universales para identificar donantes de celulas nk.
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
JOP20240086A1 (ar) معقد بولي ببتيد قابل للتنشيط
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
MY208454A (en) Anti-connective tissue growth factor antibody and application thereof
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
MX2024012474A (es) Anticuerpos anti cumulo de diferenciacion 28 (cd28) y metodos de uso de los mismos
MX2024015632A (es) Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismos
MX2025006068A (es) Proteina de union cldn18.2/4-1bb y su uso medico
RU2016148682A (ru) Антитела против рецептора-3 к эпидермальному ростовому фактору человека (her3), связывающиеся с бета-шпилькой her3